A bipartisan bill has been introduced in the US Congress that will try to block Centers for Medicare and Medicaid Services (CMS) restrictions on Biogen's Alzheimer's therapy Aduhelm being e
Biogen and Eisai are riding high on the wave of optimism set in motion by the top-line data drop for Alzheimer's therapy lecanemab – but a number of breakwaters could lie ahead.
Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically si
Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.
After a torrid couple of years, Biogen can be forgiven for making the most of new data on its tofersen drug for amyotrophic lateral sclerosis (ALS) – with an elevated status among its pipel
Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year.